Issue 09

THE PSYCH SYMPOSIUM

THE PSYCH SYMPOSIUM TO FEATURE INTERNATIONAL LEADERS FROM ACROSS THE PSYCHEDELICS INDUSTRY

Following the breaking news that Oregon will become the first state in the US to legalise psilocybin, PSYCH is delighted to welcome leaders from across the international psychedelic industry who will feature as part of The PSYCH Symposium to discuss the full implications of the vote and other key issues surrounding psilocybin legalisation.

To connect with the global psychedelics community, secure your place at our virtual event here.

BUSINESS AND INVESTMENT


Gwella launches brand house, focusing on medical and psychedelic mushrooms.


Mera Life Sciences announces innovative programme with St. Vincent and the Grenadines government.


MindMed announces completion of Phase 1 dose-finding study of LSD.


Havn Life supports German psilocybin depression study with MIND foundation.


Numinus harvests its first flush of psilocybe mushrooms in Canada.


MagicMed partners with Calgary University to expand its psychedelic patent library.


XPhyto engages German university for the development of psilocybin API production.


Nova Mentis signs amalgamation agreement to acquire Pilz BioScience.


Pharmather files for FDA orphan drug designation for ketamine in neuropathic pain.


Compass Pathways rings the Nasdaq opening bell to celebrate successful IPO.


Psychedelic wellness company Psyched Wellness commences trading on the CSE.


Pharmather secures exclusive microneedle technology for psychedelic pharmaceuticals.


Journey Colab, a start-up focused on mescaline therapy, raises US$3 million.

ST. VINCENT AND THE GRENADINES LAUNCH PSYCHEDELICS INITIATIVE

PSYCH can exclusively report that a comprehensive psychedelic medicine programme will be launched by St. Vincent and the Grenadines.

Details of the initiative have been provided by government officials, which highlight an ambition to make the islands a destination for psychedelic treatment.

“St. Vincent and the Grenadines aspires to be a medicinal and wellness destination.” – Ezra Ledger, ED of the SVG Bureau of Standards

REGULATION & LEGISLATION


Oregon voters pass Measure 109 legalising psilocybin-assisted psychotherapy.


Washington D.C. voters approve decriminalisation of psychedelic plants.


Veterans advocate decriminalisation of psychedelics to treat PTSD in Colorado Springs.

IMPACT OF PSYCHEDELIC MEDICINE LEGALISATION ON US HEALTHCARE REVEALED

Psychedelic medicines are becoming increasingly mainstream around the world as a result of significant progress being made in clinical trials and public perception shifting in favour of new and innovative therapies.

In the US alone, hundreds of billions of taxpayer dollars could be saved if, like Oregon, psychedelic medicines and assisted therapies are legalised across the country.

Download your free copy of The Psychedelics as Medicine Report: Second Edition to learn more.

RESEARCH AND SCIENCE


New research suggests benefits of microdosing psychedelics outweigh side effects.


Scientists suggest psychedelics have potential in treating COVID-19 related illnesses.


Study results show that low-dose ketamine infusion may help treat MS-related fatigue.


Over 2,400 people take part in Johns Hopkins University global psilocybin study.